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Background
Despite increasing reports of successful pregnancies
whilst using Efavirenz (EFZ), the drug remains Cate-
gory C during pregnancy due to concerns around tera-
togenicity [1]. Additionally, EFZ can render many
hormonal methods of contraception less effective. For
these reasons, UK guidance suggests that HIV positive
women should be informed of these effects before
commencing treatment [2]. Following a case in this
unit where a young HIV-positive woman had an
unplanned pregnancy whilst using Implanon and tak-
ing EFZ/Truvada, we examined contraceptive use and
advice given to women in our cohort using EFZ, and
then instigated changes to improve practice in this
area.
Methods
Case-note review of all women taking EFZ in Jan 2008
and again in Feb 2010. Current contraception used,
advice on teratogenicity, and advice on efficacy docu-
mentation was recorded. Women over 50, with docu-
mented menopause or hysterectomy were excluded.
Results
In 2008 we identified 31 females using EFZ in our
cohort of 912 patients. Contraceptive choices are shown
in Figure 1. 68% were using an ‘effective’ method of
contraception (one not liable to reduced efficacy when
using EFZ - condoms, IUS/IUD, sterilisation or recently
documented no partner). 36% had documented advice
regarding teratogenicity and 75% regarding reduced effi-
3Sandyford, Genitourinary Medicine, Glasgow, UK
Full list of author information is available at the end of the article
Figure 1
Seaton et al. Journal of the International AIDS Society 2010, 13(Suppl 4):P112
http://www.jiasociety.org/content/13/S4/P112
© 2010 Taylor et al; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.cacy of hormonal methods. Following these results we
introduced a section for contraception on our clinical
review form (which is updated at each HIV clinic
review) to act as a prompt for clinicians. After this
change was made, we re-examining these data following
this in 2010 (See Fig 1) and found 35 females using
EFZ. 80% were using an ‘effective’ method of contracep-
tion, 50% had documented advice on teratogenicity and
100% regarding reduced efficacy of hormonal contracep-
tion (if appropriate).
Conclusions
Simple changes such as adding contraception to a clinic
proforma can help improve sexual and reproductive
health outcomes in HIV positive women. However,
there are still improvements to be made in documenta-
tion of advice given, particularly when using a Category
C drug in women who may become pregnant. Addition-
ally, women should be made aware of the potential
interaction between antiretrovirals and hormonal con-
traceptives at the HIV clinic — particularly as some may
not disclose their status to Family Planning or GP ser-
vices and therefore we cannot assume that this advice is
being given elsewhere.
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